Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics raises $215.7 million in equity and $172.5 million in notes

Neutral Impact 4 of 5 financing Written later

Rapport Therapeutics closed an underwritten offering of common stock and pre-funded warrants and a $172.5 million offering of 2.25% convertible senior notes due 2032 on October 30, 2026. The company estimates net proceeds of about $215.7 million from the stock offering and $166.8 million from the notes, which it plans to use mainly to fund clinical trials of RAP-219, and it expects these funds plus existing cash to support operations through the end of 2029. Shareholders face dilution from the new shares and the potential conversion of the notes, and the company now carries a new debt obligation.

Key points

  • Stock offering: 8,333,334 firm shares at $21.00 each, plus 1,428,571 option shares exercised in full on October 28, 2026, and pre-funded warrants for up to 1,190,476 shares
  • Estimated net proceeds of $215.7 million from the stock offering and $166.8 million from the notes
  • $172.5 million of 2.25% convertible senior notes due December 1, 2032, with an initial conversion price of about $26.7750 per share
  • Notes offering closed October 30, 2026; the company says proceeds will fund operations through the end of 2029

The filing

CompanyRapport Therapeutics, Inc. (RAPP)
Form8-K, current report
Filed with the SECOct 30, 2026, 5:12 PM ET
Accession number0001193125-26-441851

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.